ImmunGene Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
6
- Investments
-
1
ImmunGene General Information
Description
Developer of therapeutic drugs designed to treat cancer, autoimmune creating disorders, and other diseases. The company's therapeutic drugs are the next generation of monoclonal antibody-based therapeutics, thereby enabling healthcare institutions to avail drugs that primarily focus on safe and effective treatments for cancer and serious diseases.
Contact Information
Website
www.immungene.comCorporate Office
- 480 Constitution Avenue
- Camarillo, CA 93012
- United States
Corporate Office
- 480 Constitution Avenue
- Camarillo, CA 93012
- United States
ImmunGene Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ImmunGene Comparisons
Industry
Financing
Details
ImmunGene Competitors (105)
One of ImmunGene’s 105 competitors is Mabworks Biotech, a Venture Capital-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mabworks Biotech | Venture Capital-Backed | Beijing, China | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY |
ImmunGene Patents
ImmunGene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2017180764-A1 | Focused interferon immunotherapy | Inactive | 12-Apr-2016 | ||
| WO-2017091611-A1 | Enhanced cancer immunotherapy using antibody-interferon fusion molecules | Inactive | 23-Nov-2015 | ||
| WO-2017087843-A1 | Methods of treating proliferative diseases using engineered antibody-interferon fusion molecules | Inactive | 20-Nov-2015 | ||
| WO-2016201350-A1 | Combination therapy for treatment of cancer | Inactive | 12-Jun-2015 | ||
| WO-2016201337-A1 | Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers | Inactive | 12-Jun-2015 | C07K14/555 |
ImmunGene Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ImmunGene Investments (1)
ImmunGene’s most recent deal was a Joint Venture with Valor Biotherapeutics. The deal was made on 13-Nov-2012.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Valor Biotherapeutics | 13-Nov-2012 | Joint Venture | Biotechnology |
ImmunGene Exits (1)
ImmunGene’s most recent exit was on 13-Nov-2012 from Valor Biotherapeutics. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Valor Biotherapeutics | 13-Nov-2012 | Completed |
|
ImmunGene FAQs
-
When was ImmunGene founded?
ImmunGene was founded in 2007.
-
Where is ImmunGene headquartered?
ImmunGene is headquartered in Camarillo, CA.
-
What industry is ImmunGene in?
ImmunGene’s primary industry is Drug Discovery.
-
Is ImmunGene a private or public company?
ImmunGene is a Private company.
-
What is ImmunGene’s current revenue?
The current revenue for ImmunGene is .
-
How much funding has ImmunGene raised over time?
ImmunGene has raised $9M.
-
Who are ImmunGene’s investors?
Ally Bridge Group, Ennovation Ventures, and WP Global Partners have invested in ImmunGene.
-
Who are ImmunGene’s competitors?
Mabworks Biotech, Inovio Pharmaceuticals, CytomX Therapeutics, Alzheon, and Cognition Therapeutics are some of the 105 competitors of ImmunGene.
-
When was ImmunGene acquired?
ImmunGene was acquired on 01-Apr-2019.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process